Comparative Pharmacology
Head-to-head clinical analysis: FLO PRED versus RAYOS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLO PRED versus RAYOS.
FLO-PRED vs RAYOS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, suppress immune response, and inhibit phospholipase A2, decreasing prostaglandin and leukotriene synthesis.
Synthetic glucocorticoid with anti-inflammatory, immunosuppressive, and metabolic effects; binds to glucocorticoid receptor, modulating gene expression and inhibiting phospholipase A2, cytokine production, and immune cell activity.
Initial: 5-60 mg orally daily in divided doses; maintenance: 5-15 mg orally daily. Also available as ophthalmic suspension (1 drop 2-4 times daily).
Initial adult dose 5-60 mg orally once daily, adjusted based on disease severity and response. Typically administered as a single dose in the morning with food.
None Documented
None Documented
The terminal elimination half-life of prednisolone is approximately 2-4 hours (mean ~3 hours) in adults with normal hepatic function. This short half-life allows for once-daily or alternate-day dosing to minimize adrenal suppression.
2-3 hours (terminal); prolonged in hepatic impairment; circadian-timed formulation intended for once-daily morning dosing.
FLO-PRED (prednisolone acetate) is primarily eliminated via hepatic metabolism, with inactive metabolites excreted renally. Approximately 20-30% of a dose is excreted unchanged in urine, and less than 5% is eliminated via biliary/fecal routes.
Renal: ~80% as inactive metabolites; fecal: ~5%; biliary: small amount.
Category C
Category C
Corticosteroid
Corticosteroid